Ziliang Kang

Dr. Ziliang Kang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Science Robotics
Verified
Journal Article
Closed access
HHHugh Herr
Hugh Herr
AAAmro Alshareef
Amro Alshareef
AHAlexandria V. Hwang
Alexandria V. Hwang
ZKZiliang Kang
Ziliang Kang
JKJohannes Kuosmanen
Johannes Kuosmanen
GTGiovanni Traverso
Giovanni Traverso
Oral drug delivery of proteins is limited by the degradative environment of the gastrointestinal tract and poor absorption, requiring parenteral administration of these drugs. Luminal mucus represents the initial steric and dynamic barrier to absorption. To overcome this barrier, we report the development of the RoboCap, an orally ingestible, robotic drug delivery capsule that locally clears the mucus layer, enhances luminal mixing, and topically deposits the drug payload in the small intestine to enhance drug absorption. RoboCap’s mucus-clearing and churning movements are facilitated by an internal motor and by surface features that interact with small intestinal plicae circulares, villi, and mucus. Vancomycin (1.4 kilodaltons of glycopeptide) and insulin (5.8 kilodaltons of peptide) delivery mediated by RoboCap resulted in enhanced bioavailability 20- to 40-fold greater in ex vivo and in vivo swine models when compared with standard oral delivery ( P < 0.05). Further, insulin delivery via the RoboCap resulted in therapeutic hypoglycemia, supporting its potential to facilitate oral delivery of drugs that are normally precluded by absorption limitations.

14 September 2022 in Nature Reviews Materials
Verified
Journal Article
Closed access
PDF file
KNKewang Nan
Kewang Nan
VFVivian R. Feig
Vivian R. Feig
BYBinbin Ying
Binbin Ying
JHJulia G. Howarth
Julia G. Howarth
ZKZiliang Kang
Ziliang Kang
GTGiovanni Traverso
Giovanni Traverso

23 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
ZKZiliang Kang
Ziliang Kang
JGJohanna A. Gomez
Johanna A. Gomez
ARAlisa MeiShan Ross
Alisa MeiShan Ross
AKAmeya R. Kirtane
Ameya R. Kirtane
MZMing Zhao
Ming Zhao
GTGiovanni Traverso
Giovanni Traverso
Achieving long-term underwater adhesion to dynamic, regenerating soft substrates that undergo extreme fluctuations in pH and moisture remains a major unresolved challenge, with far-reaching implications for healthcare, manufacturing, robotics and marine applications1–16. Here, inspired by remoras—fish equipped with specialized adhesive discs—we developed the Mechanical Underwater Soft Adhesion System (MUSAS). Through detailed anatomical, behavioural, physical and biomimetic investigations of remora adhesion on soft substrates, we uncovered the key physical principles and evolutionary adaptations underlying their robust attachment. These insights guided the design of MUSAS, which shows extraordinary versatility, adhering securely to a wide range of soft substrates with varying roughness, stiffness and structural integrity. MUSAS achieves an adhesion-force-to-weight ratio of up to 1,391-fold and maintains performance under extreme pH and moisture conditions. We demonstrate its utility across highly translational models, including in vitro, ex vivo and in vivo settings, enabling applications such as ultraminiaturized aquatic kinetic temperature sensors, non-invasive gastroesophageal reflux monitoring, long-acting antiretroviral drug delivery and messenger RNA administration via the gastrointestinal tract.

10 October 2024 in eClinicalMedicine
Verified
Journal Article
Open access
VFVivian Rachel Feig
Vivian Rachel Feig
SZSufeng Zhang
Sufeng Zhang
APAshka Patel
Ashka Patel
BSBruna Santos
Bruna Santos
ZKZiliang Kang
Ziliang Kang
GTGiovanni Traverso
Giovanni Traverso
Biotherapeutics are among the therapeutics that have revolutionized standard inflammatory bowel disease (IBD) treatment, which was previously limited to mesalamine, 5-aminosalicylic acid, corticosteroids, and classical immunosuppressants. Self-administrable biotherapeutics for IBD would enable home-based treatment and reduce the burden on medical infrastructure. Self-administration is made possible through subcutaneous injectable, oral, and rectal dosage forms. Nevertheless, the full benefits of self-administration cannot be realized without first addressing the issue of medication adherence, which remains woefully inadequate for IBD biotherapies. Some of the major barriers to medication adherence in IBD are the route of administration, frequency of administration, and undesired side effects. In this review, we identify the main physiological and engineering constraints that underlie these three barriers to adherence. We then highlight key technological and behavioral innovations-spanning multiple scientific disciplines-that can be leveraged to design novel therapies and interventions that improve adherence to self-administered IBD biotherapies.

7 April 2021 in Journal of Dynamic Systems, Measurement, and Control
Verified
Journal Article
Closed access
PDF file
DDDonald J. Docimo
Donald J. Docimo
ZKZiliang Kang
Ziliang Kang
KJKai A. James
Kai A. James
AAAndrew G. Alleyne
Andrew G. Alleyne
This article explores the optimization of plant characteristics and controller parameters for electrified mobility. Electrification of mobile transportation systems, such as automobiles and aircraft, presents the ability to improve key performance metrics such as efficiency and cost. However, the strong bidirectional coupling between electrical and thermal dynamics within new components creates integration challenges, increasing component degradation, and reducing performance. Diminishing these issues requires novel plant designs and control strategies. The electrified mobility literature provides prior studies on plant and controller optimization, known as control co-design (CCD). A void within these studies is the lack of model predictive control (MPC), recognized to manage multi-domain dynamics for electrified systems, within CCD frameworks. This article addresses this through three contributions. First, a thermo-electromechanical hybrid electric vehicle (HEV) powertrain model is developed that is suitable for both plant optimization and MPC. Second, simultaneous plant and controller optimization is performed for this multi-domain system. Third, MPC is integrated within a CCD framework using the candidate HEV powertrain model. Results indicate that optimizing both the plant and MPC parameters simultaneously can reduce physical component sizes by over 60% and key performance metric errors by over 50%.

29 December 2021 in Structural and Multidisciplinary Optimization
Verified
Journal Article
Closed access
PDF file
ZKZiliang Kang
Ziliang Kang
KJKai A. James
Kai A. James